Lupin has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey. The EIR has been issued with a Voluntary Action Indicated (VAI) classification, confirming compliance with manufacturing standards. This outcome is critical for the company as it ensures uninterrupted supply from the facility to the U.S. market, reinforcing its commitment to quality and operational excellence.

The inspection at the Somerset facility was conducted from April 13, 2026, to April 17, 2026. Following the review, the U.S. FDA determined that any observations made during the inspection do not warrant regulatory action. Nilesh Gupta, Managing Director, Lupin, stated that the outcome reflects the company's unwavering commitment to quality, compliance, and operational excellence.

Regulatory Outcome at Somerset Facility

The issuance of an EIR with VAI status indicates that the U.S. FDA has completed its review of the facility inspection. VAI is one of the most favorable classifications a facility can receive following a U.S. FDA inspection.

Significance of VAI Classification

A VAI classification from the U.S. FDA signifies that, while observations may have been noted during the inspection, they are not considered significant enough to require mandatory corrective action by the company. This outcome is widely regarded as a positive regulatory signal for pharmaceutical manufacturers operating in the U.S. market. The Somerset facility's receipt of this status underscores Lupin's compliance posture at this manufacturing site.

Lupin announced that the European Medicines Agency (EMA) has approved an expansion of the marketing authorization for NaMuscla to include pediatric indications. The approval, supported by a Pediatric Investigation Plan (PIP), introduces two new dosage strengths of 62 mg and 83 mg capsules, supplementing the existing 167 mg strength. This regulatory change allows for the symptomatic treatment of myotonia in children aged 6–11 years weighing at least 20 kg, adolescents aged 12–17 years, and adults aged 18 years and older with non-dystrophic myotonic disorders.

Key Approval Parameters

The EMA's decision broadens the scope of NaMuscla, which is the only approved treatment for myotonia symptoms in non-dystrophic myotonic disorders (NDM) in Europe. The following table outlines the specific details of the expanded authorization:

Strategic Significance

The addition of lower dosage strengths addresses the specific therapeutic needs of pediatric patients, who often require weight-adjusted dosing compared to adults. Claus Jepsen, President, Global Specialty at Lupin, highlighted that this approval represents a significant step forward for patients and families living with non-dystrophic myotonic disorders, particularly where options for children are scarce. The company is now working towards making these new dosage strengths available across Europe, subject to local implementation timelines and national reimbursement processes.

Disease Context

Non-dystrophic myotonias are rare, inherited neuromuscular disorders characterized by an inability to relax muscle contractions, impacting daily activities such as walking or grasping objects. With a prevalence of 1 in 100,000, these conditions often present in childhood and persist throughout a patient's lifetime. The expansion of NaMuscla's label aims to address the substantial delays in diagnosis and treatment often faced by this patient demographic.